Effect of PPV on retinal vessel oxygen saturation

Article

PPV has been a major advancement in the treatment of retinal diseases, however, little is known about its effect on oxygen metabolism in retinal vessels. In this article, Dr Sin reveals the results of his pilot study examining the effect of PPV on the oxygen saturations in retinal vessels.

The retina has a high demand for oxygen and starvation of this element in retinal vessels is considered to be an important factor in certain diseases, such as diabetic retinopathy and glaucoma.1 To examine the effect of PPV on oxygen saturation in retinal vessels a new tool, oximetry,2 was employed, explained Dr Martin Šín (Department of Ophthalmology, University Hospital Olomouc, The Czech Republic) when discussing the initial reasoning behind his recent pilot study.3 "Our head of department, Professor J. Rehak, has been researching retinal vein occlusion for many years. In 2011, he bought an automatic retinal oximetry (Oxymap, Reykjavik, Iceland) device allowing us to investigate the oxygen saturation in retinal vessels," he said.

Investigating the influence of PPV

Oximetry was performed 24 hours before PPV and then ranging between 42 and 49 days after PPV, which was either 20G or sutureless 23G. Oxygen saturation levels were examined in both retinal arteries and veins and vessel segments of first or second degree were selected. These specific segments were analysed before and after PPV to determine whether there was any change or effect of the surgery on oxygen saturation. The comparison of this data was performed using two-tailed t-test.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.